Dwyer Benjamin J, Tirnitz-Parker Janina E E
Curtin Medical School and Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia; Liver Cancer Collaborative, Perth, WA, Australia; www.livercancercollaborative.au.
Trends Endocrinol Metab. 2025 Mar;36(3):235-248. doi: 10.1016/j.tem.2024.07.019. Epub 2024 Aug 26.
Liver diseases represent a growing global health challenge, and the increasing prevalence of obesity and metabolic disorders is set to exacerbate this crisis. To meet evolving regulatory demands, patient-specific in vitro liver models are essential for understanding disease mechanisms and developing new therapeutic approaches. Organoid models, which faithfully recapitulate liver biology, can be established from both non-malignant and malignant liver tissues, offering insight into various liver conditions, from acute injuries to chronic diseases and cancer. Improved understanding of liver microenvironments, innovative biomaterials, and advanced imaging techniques now facilitate comprehensive and unbiased data analysis, paving the way for personalised medicine. In this review, we discuss state-of-the-art patient-derived liver organoid models, recent technological advancements, and strategies to enhance their clinical impact.
肝脏疾病是全球日益严峻的健康挑战,肥胖和代谢紊乱患病率的上升将加剧这一危机。为满足不断变化的监管要求,针对特定患者的体外肝脏模型对于理解疾病机制和开发新治疗方法至关重要。类器官模型能够忠实地重现肝脏生物学特性,可从非恶性和恶性肝脏组织中建立,有助于深入了解从急性损伤到慢性疾病及癌症等各种肝脏疾病状况。对肝脏微环境的深入理解、创新生物材料和先进成像技术,如今有助于进行全面且无偏差的数据分析,为个性化医疗铺平道路。在本综述中,我们讨论了最新的患者来源肝脏类器官模型、近期技术进展以及增强其临床影响力的策略。